These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26646310)

  • 1. [Determination of prognosis using gene expression analyses: Consequences for the indication for radiotherapy?].
    Baumann R; Krug D
    Strahlenther Onkol; 2016 Feb; 192(2):136-8. PubMed ID: 26646310
    [No Abstract]   [Full Text] [Related]  

  • 2. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
    Fitzal F; Filipits M; Rudas M; Greil R; Dietze O; Samonigg H; Lax S; Herz W; Dubsky P; Bartsch R; Kronenwett R; Gnant M
    Br J Cancer; 2015 Apr; 112(8):1405-10. PubMed ID: 25867274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2- Breast Cancer?
    Amlicke MJ; Spanheimer PM
    Ann Surg Oncol; 2022 Nov; 29(12):7670-7671. PubMed ID: 35831528
    [No Abstract]   [Full Text] [Related]  

  • 5. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
    Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
    Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
    Shi YJ; Tsang JY; Ni YB; Tse GM
    Oncologist; 2017 Apr; 22(4):487-490. PubMed ID: 28341760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the value of the 21 gene recurrence score in HER2-negative patients?
    Rosman M; Mylander WC; Tafra L
    J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.
    Kaklamani VG; Cianfrocca M; Ciccone J; Kindy K; Rademaker A; Wiley EL; Gradishar W; O'Regan RM
    Biomarkers; 2010 Mar; 15(2):191-3. PubMed ID: 19839717
    [No Abstract]   [Full Text] [Related]  

  • 10. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
    PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
    Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
    Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal oestrogen receptor in clinical breast cancer.
    McGuire WL; Chamness GC; Fuqua SA
    Eur J Cancer; 1992; 28(2-3):309-10. PubMed ID: 1591044
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
    Ongaro E; Gerratana L; Cinausero M; Pelizzari G; Poletto E; Giangreco M; Andreetta C; Pizzolitto S; Di Loreto C; Minisini AM; Mansutti M; Russo S; Fasola G; Puglisi F
    Future Oncol; 2018 Apr; 14(9):849-859. PubMed ID: 29527957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
    Wolf I; Ben-Baruch N; Shapira-Frommer R; Rizel S; Goldberg H; Yaal-Hahoshen N; Klein B; Geffen DB; Kaufman B
    Cancer; 2008 Feb; 112(4):731-6. PubMed ID: 18076012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting late recurrence in ER-positive breast cancer.
    Cuzick J
    Nat Rev Clin Oncol; 2019 Jul; 16(7):406-408. PubMed ID: 31092902
    [No Abstract]   [Full Text] [Related]  

  • 20. The prognostic value of triple negative in stage II/III breast cancer.
    Elnashar AT; Ali el-SM; Gaber A
    J Oncol Pharm Pract; 2012 Mar; 18(1):68-75. PubMed ID: 21422149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.